Kiora Pharmaceuticals
KPRX
13 hedge funds and large institutions have $391K invested in Kiora Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
13% less funds holding
Funds holding: 15 → 13 (-2)
24% less capital invested
Capital invested by funds: $517K → $391K (-$126K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$21.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.03K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$7.03K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$837 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$24.1K |
| 2 |
E
Ergoteles
New York
|
-$11K |
| 3 |
Goldman Sachs
New York
|
-$8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $257K | +$8.03K | +48 | +3% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $31K | -$4.52K | -27 | -13% |
|
3
T. Rowe Price Associates
Baltimore,
Maryland
| $24K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $22K | +$21.6K | +129 | New |
|
|
5
Renaissance Technologies
New York
| $20K | -$24.1K | -144 | -55% |
|
|
6
UBS Group
Zurich,
Switzerland
| $13K | +$13.2K | +79 | +7,900% |
|
7
BlackRock
New York
| $10K | – | – | – |
|
|
8
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $7K | +$7.03K | +42 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $6K | +$837 | +5 | +17% |
|
10
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
E
11
Ergoteles
New York
| – | -$11K | -49 | Closed |
|
|
12
Goldman Sachs
New York
| – | -$8K | -37 | Closed |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$7K | -31 | Closed |
|
14
Citigroup
New York
| – | -$1K | -3 | Closed |
|
15
Osaic Holdings
Scottsdale,
Arizona
| – | +$167 | +1 | +33% |
|
KPRX Hedge Fund Activity: Q2 2022 in Review
13 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2022, worth a combined $391K — down 24% from $517K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of KPRX and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $21.6K. The largest seller was Renaissance Technologies, cutting an estimated $24.1K.
- 13 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2022, down from 15 in Q1 2022.
- Funds reported $391K of Kiora Pharmaceuticals stock for Q2 2022, down 24% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q2 2022 and 4 closed out, a net change of -2 holders.
- The largest Kiora Pharmaceuticals buyer in Q2 2022 was Citadel Advisors, an estimated $21.6K added.
- The largest Kiora Pharmaceuticals seller in Q2 2022 was Renaissance Technologies, an estimated $24.1K sold.
Based on aggregated 13F filings for Q2 2022.